1. Medtech Insight
  2. >>Device Area
  3. >>Combination Products

UDI Database Deadline Extended Again For Certain Combo Products

Following an extension for Unique Device Identifier requirements for low-risk devices earlier this summer, US FDA has pushed back a deadline to input UDI date into its GUDID database for combination products that go through the drug center. Manufacturers, however, are still required to implement UDIs labeling by Sept. 24.

Makers of certain drug-device or biologic-device combination products have an extra year to comply with US FDA's requirement to submit Unique Device Identifier (UDI) data into its Global Unique Device Identification Database (GUDID). The agency says it needs the extra time to update the GUDID system but also notes such products will still need to adopt UDI on product labeling by Sept. 24, 2018.

Makers of the co-packaged combination products that are assigned to the Center for Drug Evaluation and Research (CDER) as a lead center now have until Sept. 24, 2019, to comply...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Combination Products

More from Device Area

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.